A5003347715- Extracellular vesicles in disease
- Cancer Genomics and Diagnostics
- Cancer Cells and Metastasis
- MicroRNA in disease regulation
- Single-cell and spatial transcriptomics
- Neurogenetic and Muscular Disorders Research
- RNA Research and Splicing
- Amyotrophic Lateral Sclerosis Research
- Microfluidic and Bio-sensing Technologies
- Nanopore and Nanochannel Transport Studies
- Cell Adhesion Molecules Research
- Biosensors and Analytical Detection
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Lung Cancer Treatments and Mutations
- 3D Printing in Biomedical Research
- Pancreatic function and diabetes
- Immune cells in cancer
- Complement system in diseases
- Pancreatic and Hepatic Oncology Research
- Immune Cell Function and Interaction
- Nanoplatforms for cancer theranostics
- Microfluidic and Capillary Electrophoresis Applications
- Medical Imaging and Pathology Studies
- Epigenetics and DNA Methylation
Mayo Clinic in Florida
2024
Mayo Clinic
2024
Mayo Clinic in Arizona
2024
University of Michigan
2018-2022
BioSurfaces (United States)
2019-2021
Ann Arbor Center for Independent Living
2019-2020
Michigan Cancer Research Consortium
2020
Abstract Extracellular vesicles (EVs) are emerging as a potential diagnostic test for cancer. Owing to the recent advances in microfluidics, on‐chip EV isolation is showing promise with respect improved recovery rates, smaller necessary sample volumes, and shorter processing times than ultracentrifugation. Immunoaffinity‐based microfluidic using anti‐CD63 widely used; however, not specific cancer‐EVs, some cancers secrete EVs low expression of CD63. Alternatively, phosphatidylserine (PS),...
As the recognition between natural killer (NK) cells and cancer does not require antigen presentation, NK are being actively studied for use in adoptive cell therapies rapidly evolving armamentarium of immunotherapy. In addition to utilizing cells, recent studies have shown that exosomes derived from also exhibit antitumor properties. Furthermore, these cell-derived higher stability, greater modification potentials less immunogenicity compared cells. Therefore, technologies allow highly...
Melanoma is among the most aggressive cancers, and its rate of incidence continues to grow. Early detection melanoma has been hampered due lack promising markers for testing. Recent advances in liquid biopsy have proposed noninvasive alternatives cancer diagnosis monitoring. Circulating tumor cells (CTCs) cancer-exosomes are gaining influence as biomarkers because their cancer-associated molecular signatures. However, technologies that offer dual-isolation CTCs exosomes using a single sample...
Immunoaffinity based EV isolation technologies use antibodies targeting surface markers on EVs to provide higher specificity and purity compared existing approaches.
Amyotrophic lateral sclerosis (ALS) is a terminalneurodegenerative disease. Clinical and molecular observations suggest that ALS pathology originates at single site spreads in an organized prion-like manner, possibly driven by extracellular vesicles. Extracellular vesicles (EVs) transfer cargo molecules associated with pathogenesis, such as misfolded aggregated proteins dysregulated microRNAs (miRNAs). However, it poorly understood whether altered levels of circulating or their components...
PD1/PD-L1 checkpoint inhibitors are at the forefront of cancer immunotherapies. However, overall response rate remains only 10-30%. Even among initial responders, drug resistance often occurs, which can lead to prolonged use a futile therapy in race with fatal disease. It would be ideal closely monitor key indicators patients' immune responsiveness, such as circulating PD-L1 levels. Traditional detection methods, ELISA, limited sensitivity and rely on core lab facilities, preventing their...
We present a simple strategy to immobilize and analyze extracellular vesicles for multiple markers on microfluidic device, called DICE.
While cancer cell populations are known to be highly heterogeneous within a tumor, the current gold standard of tumor profiling is through biopsy. These biopsies invasive and prone missing these clones due spatial heterogeneity, this bulk analysis approach can miss information from rare subpopulations. To noninvasively investigate streamlined workflow developed scrutinize cells, such as circulating cells (CTCs), for simultaneous mutations gene expression profiles at single level. This...
The functional membrane proteins on tumor-cell-derived EVs contain a large amount of biomolecular information, and can serve as comprehensive marker to delineate the molecular nature cancer. However, due low secretion rates, it is difficult perform accurate quantification analysis with conventional EV technologies such Western blots. Here, we introduce multifunctional technology based an automated microfluidic chemiluminescent ELISA (Enzyme-Linked ImmunoSorbent Assay) platform. With this...
In non-small cell lung cancer (NSCLC), identifying the presence of sensitizing and resistance epidermal growth factor receptor (EGFR) mutations dictates treatment plans. Extracellular vesicles (EVs) are emerging as abundant, stable potential liquid biopsy targets that offer to quantify EGFR in NSCLC patients at RNA protein level multiple points through treatment. this study, we present a systematic approach for serial mutation profiling 34 EV samples from 10 metastatic with known Using...
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease. Its complex pathogenesis and phenotypic heterogeneity hinder therapeutic development early diagnosis. Altered RNA metabolism recurrent pathophysiologic theme, including distinct microRNA (miRNA) profiles in ALS tissues. We profiled miRNAs accessible biosamples, skin fibroblasts whole blood compared them age- sex-matched healthy controls versus participants with without repeat expansions to chromosome 9 open reading...
Abstract Background. Extracellular vesicles (EV) are emerging as new biomarkers for cancer diagnostics and therapeutic monitoring1. For example, in patients that receive PD1/PD-L1 immune checkpoint inhibitors (a key pillar of immunotherapy), circulating EV-derived PD-L1 is gaining attention a non-invasive biomarker efficacy. Standard methodologies to measure requires ultracentrifugation first separate EVs then quantify those express using nano flow cytometry. These tedious processes require...
Abstract With the aim of personalized medicine, there have been many targeted therapies developed against cancer-specific antigens. The efficacy was first shown in lung cancer patients containing activating epidermal growth factor receptor (EGFR) mutations who responded to tyrosine kinase inhibitors. Despite promise these EGFR therapies, routinely acquire an additional mutation, T790M, which causes treatment resistance. In order determine if a patient qualifies for therapy, they must get...
Abstract Introduction: Melanoma is among the most aggressive cancers, and its incidence continues to grow. Due lack of promising markers predict disease onset metastasis, early detection evaluation treatment efficacy have been hampered. Recent advances in liquid biopsy proposed alternatives for diagnosing with merits enabling continuous monitoring non-invasiveness. CTCs cancer exosomes are evolving as biomarkers due their innate capability having cancer-associated molecules signatures....
In the era of personalized medicine, many targeted therapies have been developed against cancer-specific antigens, which greatly improved patient outcome. The efficacy was first shown in patients with non-small cell lung cancer (NSCLC) containing activating epidermal growth factor receptor (EGFR) mutations who responded to tyrosine kinase inhibitors (TKIs). To determine if a qualifies for therapy, must undergo tumor biopsy. Usually done at time diagnosis, this single time-point examination...
Introduction: Melanoma is among the most aggressive cancers, and its incidence continues to grow. Due lack of promising markers predict disease onset metastasis, early detection evaluation treatment efficacy have been hampered. Recent advances in liquid biopsy proposed alternatives for diagnosing with merits enabling continuous monitoring non-invasiveness. CTCs cancer exosomes are evolving as biomarkers due their innate capability having cancer-associated molecules signatures. However,...
Abstract In the era of personalized medicine, many targeted therapies have been developed against cancer-specific antigens, which greatly improved patient outcome. The efficacy was first shown in patients with non-small cell lung cancer (NSCLC) containing activating epidermal growth factor receptor (EGFR) mutations who responded to tyrosine kinase inhibitors (TKIs). To determine if a qualifies for therapy, must undergo tumor biopsy. Usually done at time diagnosis, this single time-point...
Abstract The efficacy of targeted therapies was first shown in patients with non-small cell lung cancer (NSCLC) who possess activating epidermal growth factor receptor (EGFR) mutations that responded to tyrosine kinase inhibitors (TKIs). Current standard care is screen metastatic for the presence EGFR determine if they qualify TKI treatment. Due invasiveness a tumor biopsy, this characterization typically only done at time diagnosis. This single time-point determines entire treatment plan....
Abstract Introduction: Extracellular vesicles (EV), recovered from a liquid biopsy, are emerging as putative diagnostic test for cancer. To date, ultracentrifugation has been accepted the gold standard EV isolation despite its lengthy processing time and low recovery rate. Thanks to recent technological advances in microfluidics, several microfluidic devices have developed showing promise with respect improved rates, ability extract EVs small sample volumes, shorter compared...